Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / VEGFA



This biomarker is also known as:
  • VEGF,
  • vascular endothelial growth factor,
  • Vascular permeability factor,
  • VPF,
  • VEGF-A,
  • MVCD1,
  • vascular endothelial growth factor A,

View in BioMuta


Vascular endothelial growth factor (VEGFA or VEGF) is a growth factor and signaling protein involved in the regulation of angiogenesis, vasculogenesis, and endothelial cell grown. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Three VEGFR isoforms have been identified in humans; VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). VEGFR-2 mediates the majority of cellular responses to VEGF. VEGFR-1 is thought to modulate VEGFR-2 signaling or to act as a dummy/decoy receptor to sequester VEGF away from VEGFR-2.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


Preclinical and clinical studies have suggested that VEGFA is important in human breast cancer.

Performance Comment

VEGFA was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.



Phase: Two
QA State: Under Review


Elevated levels of VEGFA in serum and tumor tissue are associated with poor prognosis in patients with lung cancer.

Performance Comment

Levels of angiogenic markers FGF2, ANG, and VEGFA in exhaled breath condensate significantly discriminated between 17 individuals with newly detected non-small cell lung cancer versus stable and exacerbated chronic obstructive pulmonary disease (COPD).


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.